TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE

比较阿霉素和环磷酰胺佐剂随后泰索帝的试验

• 批准号: 7376247
• 负责人: WILLIAM MCKINNON
• 金额: $ 0.17万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376247
• 关键词: TRIAL; COMPARE; ADJUVANT; ADRIAMYCIN; CYCLOPHOSPHAMIDE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this phase III trial are to determine whether four cycles of post-operative Adriamycin (A:60mg/m2), Taxotere (T:60mg/m2), and Cyclophosphamide (C:600mg/m2) administered concurrently will more effectively prolong disease-free survival (DFS) and overall survival (S) of patients with node-positive breast cancer than will four cycles of AC (A:60mg/m2 and C:600mg/m2) followed by four cycles of T (100mg/m2); and if four cycles of post-operative AT (A:60mg/m2 and T:60mg/m2) is at least as efficacious as the above two regimens containing cyclophosphamide.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项III期试验的主要目的是确定四个术后adriamycin（a：60mg/m2）的周期（t：60mg/m2）和环磷酰胺（c：600mg/m2）是否同时同时培养了与疾病生存（dfs carryvials and carrical carrical and carrical and）（c：600mg/m2）的施加（600mg/m2），并将其用于较大的乳房（dfs）（dfs and）。 AC（A：60mg/m2和C：600mg/m2），然后是四个循环（100mg/m2）；如果在（a：60mg/m2和t：60mg/m2）的术后四个循环至少与上述两个含有环磷酰胺的方案一样有效。